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Chronic allograft rejection: A signifi cant hurdle 
to transplant success
Introduction
There are three major types of allograft rejection: Hyperacute, 
acute, and chronic rejection.[1] Hyperacute rejection occurs 
within minutes and hours after transplantation and is caused 
by the presence of  preexisting antidonor antibodies in the 
recipient blood. Recognition of  donor antibody activates 
the complement system, induces influx of  neutrophils, 
and promotes coagulation. The resulting inflammation 
and ischemia induce irreversible damage of  the graft. 
Fortunately, existing screenings for antidonor antibodies 
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eliminate most of  hyperacute rejection cases. Acute 
rejection occurs within the first weeks to several months 
after transplantation and usually affects every transplanted 
organ to some degree. Acute rejection is caused by the 
mismatch in highly polymorphic human leukocyte antigens 
(HLA) and is mediated primarily by T cells. They produce 
cytokines upon activation, which recruit inflammatory 
cells eventually leading to necrosis of  graft tissue. Presently, 
the acute rejection can be successfully contained by 
immunosuppressive therapies.
Chronic rejection develops within months to years after 
transplantation and is the major cause of  long-term graft 
loss. The main feature of  chronic rejection is accelerated 
arteriosclerosis or progressive luminal narrowing of  graft 
vessels (vasculopathy or graft vascular disease (GVD)) often 
accompanied by graft tissue (parenchymal) fibrosis. These, 
in turn, result in ischemia, cell death, and graft failure. All 
the existing immunosuppressive regimens are highly focused 
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on prevention of  acute rejection, and at present there are no 
available antichronic rejection therapies. Thus, understanding 
the cellular and molecular events contributing to chronic 
rejection of  transplanted organs is pivotal for development 
of  novel antichronic rejection therapies.
Transplant vasculopathy
One of  the most distinctive features of  chronic rejection of  
heart, kidney, liver, and lung allografts is the progressive 
occlusion or intimal hyperplasia of  the blood vessels, 
which compromises blood flow and results in ischemia and 
eventual failure of  the graft.[2]
Normal blood vessel is built of  several distinct layers [Figure 
1].[1] The most inner (facing the lumen/blood) and also the 
thinnest layer called the tunica intima (or intima) consists 
of  a single layer of  endothelial cells positioned on a layer 
extracellular matrix composed of collagen and proteoglycans 
and a sheet of  elastic fibers called the internal lamina. The 
second (middle layer) called the tunica media (or media) 
consists of smooth muscle cells (SMCs) embedded in elastin-
rich extracellular matrix and positioned on external elastic 
lumina [Figure 1]. The outer layer, the tunica adventitia (also 
called tunica externa or adventitia) is built of  connective 
tissue with interspersed fibroblasts, quiescent resident 
inflammatory cells, myofibroblasts, recently identified 
large population of  resident stem/progenitor cells[3,4] 
and autonomic nerve endings [Figure 1].[1,5-7] All these 
constituents of  blood vessels undergo profound remodeling 
during chronic rejection.
Vascular remodeling in chronic rejection
Although the narrowing of  vessel lumen can be caused 
by one of  the three major types of  vascular remodeling: 
Thickening of  the intima (through the recruitment of  
extraneous smooth muscle cells and some leukocytes), 
constrictive remodeling (when a healing response in the 
adventitia results in the formation of  collagen-rich scar 
tissue, which squeezes the media and intima inward),[8] 
and vasoconstriction (a hypercontraction of  smooth muscle 
cells in the tunica media) [Figure 2]; the intimal thickening 
(formation of  neointima) seems to play a dominant role in 
vascular remodeling during chronic rejection.[1,2,5-7]
There are two major hypotheses concerning the initiation 
of  vascular remodeling and inflammatory response. 
Traditional concept called the “inside-out” response 
assumes that the inflammatory response to various types of  
injuries (including immune injury during chronic rejection) 
is initiated at the endothelial layer of  the intima, that is, 
at the luminal (inside) surface of  the vessel [Figure 3]. 
According to this “inside-out” hypothesis the first target 
of  chronic alloresponse and inflammatory response is 
the vascular endothelium, which produces cytokines, 
chemokines, and adhesion molecules leading to the 
accumulation of  leukocytes (predominantly macrophages). 
Figure 1: Blood vessel composition. Large blood (arteries and veins) 
vessels are composed of three layers (shown here out of proportion). 
Tunica intima (the thinnest layer, facing the blood) contains a single 
layer of endothelial cells positioned on subendothelial extracellular 
matrix and circularly arranged elastic bands called the internal elastic 
lamina. Tunica media (which is the thickest layer in arteries) is 
composed of extracellular matrix, smooth muscle cells (SMCs) and 
thick elastic band called external elastic lamina. Tunica adventitia 
(which is the thickest layer in veins) is made of connective tissue with 
interspersed fi broblasts and stem/progenitor cells. It also contains 
nerve endings and nutrient capillaries (vasa vasorum) in the larger 
blood vessels.
Figure 2: Vascular remodeling: (a) Diagram of normal blood vessel. (b) 
Thickening of the intima, through the recruitment and proliferation of 
smooth muscle cells, is dominant form of vascular remodeling in chronic 
rejection. (c) Constrictive remodeling caused by a healing response 
and formation of scar tissue in the adventitia results in squeezing the 
media and intima inward. (d) Vasoconstriction is caused by reversible 
over contraction of smooth muscle cells in the tunica media.
a
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In addition, oxidized lipids in the circulation accumulate 
in the macrophages, which are present on the surface of  
the intima leading to endothelial cells injury and initiation 
an inflammatory process. Subsequently, endothelial 
cells and activated macrophages produce growth factors, 
which together with interferon-γ produced by T cells 
(and subsequently in autonomic loop by macrophages 
and SMCs), stimulate SMCs of  the media to change the 
phenotype [Figure 3].[3,4,9-13] After further stimulation, the 
SMCs residing in the media acquire proliferative phenotype 
and transmigrate into the subendothelial layer of  intima 
leading to progressive decellularization of  the media, 
thickening of  the intima (formation of  the neointima), and 
progressive occlusion of  the vessel [Figures 3 and 4].[14,15] 
The fact that there is progressive loss (especially dramatic 
in chronic rejection) of  the SMCs from the media and 
that neointimal cells express α-actin (which is a specific 
marker of  smooth muscle cells) has been considered as a 
proof  of  principle that neointimal cells may actually derive 
from the SMCs of  the donor vessel media.[9,11] Recently, 
there is mounting evidence supporting a new “outside-in” 
hypothesis in which the inflammatory response is initiated 
at the outer layer of  the vessel, that is, at the adventitia and 
propagates inwards toward the intima [Figure 3]. According 
to this hypothesis the adventitial inflammation results in 
the production of  cytokines and growth factors, which 
stimulate phenotypic switch of  resident progenitor or stem 
cells and/or resident fibroblasts into migratory cells, which 
after migration into intima can differentiate into α-actin-
producing SMCs [Figure 3].[3,4] Studies using the acute 
vascular injury models indicate that indeed the adventitia 
contains a resident population of  vascular progenitor cells 
that are able to differentiate into SMCs and then migrate 
from the adventitia to the forming neointima [Figures 3 
and 4].[5,16]
Origin of SMCs in intimal thickening
Although it is well-established that the thickening of  the 
intima is the results of  migration of  extraneous cells into 
the intima [Figure 3]. In the past few decades, there has 
been much controversy about the source and identity of  
these cells. [3,5,11,17,18] The generally accepted hypothesis, 
mostly based on the response-to-injury model of  host 
native atherosclerosis setting, assumes that both in “inside-
in” and “outside-in” scenario the SMCs of  neointima 
originate from the vessel wall (either from the media or from 
adventitia) of  the donor vessel. However, the assumption 
that SMCs originate exclusively from the donor has been 
recently challenged [Figure 4].[5,11,18] Using mouse vascular 
mechanical injury as a model of  neointima formation in 
native atherosclerosis, Han et al.,[19] showed that neointimal 
cells can derive (at least partially) from the recipient bone 
Figure 3: Hypotheses of vascular injury. (a) In the “inside-out” 
hypothesis the fi rst target of injury is vascular endothelium, which 
produces inflammatory and adhesion molecules leading to the 
accumulation of leukocytes (macrophages, neutrophils and interferon-γ 
producing T cells). Endothelial cells and activated macrophages 
produce growth factors, which together with interferon-γ produced 
by T cells (and subsequently in autonomic loop by macrophages and 
SMCs), stimulate the SMCs residing in the media to acquire proliferative 
phenotype and migrate to the intima. This leads to progressive loss 
of SMCs from the media and thickening of the intima (formation of the 
neointima). (b) In the “outside-in” hypothesis the infl ammatory response 
is initiated at the adventitia and progresses inward. Signaling from the 
infl amed adventitia leads to apoptosis of resident SMCs of media. In 
addition, it results in the production of cytokines and growth factors, 
which induce phenotypic switch of adventitia progenitor/stem cells and/
or resident fi broblasts into migratory cells; which migrate to the intima, 
proliferate, and differentiate into SMCs.
a
b
Figure 4: Hypothetical origin of neointimal SMCs. (a) SMCs of the 
media (after switching into migratory phenotype) transmigrate into 
newly forming neointima. (b) SMCs present in the media undergo 
apoptosis. Stem/progenitor cells and resident fi broblasts present in 
adventitia acquire migratory phenotype and transmigrate into intima 
where they proliferate and differentiate into SMCs. (c) SMCs present 
in the media undergo apoptosis. Bone marrow progenitor cells (and 
possibly also circulation-derived CD34+ hematopoietic progenitor cells) 
acquire migratory phenotype, migrate into the intima, proliferate, and 
differentiate into SMCs.
X XX XX X X
X XX XX X X
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marrow cells expressing smooth muscle specific α-actin. 
Although these data support the hypothesis of  recipient 
origin of  neointimal cells in native atherosclerosis, they 
do not prove that the same process occurs during chronic 
transplant rejection. To address this issue, Skaro et al.,[11] 
attempted to address the mechanism responsible for the 
loss of  SMCs from the media during chronic rejection. The 
question the authors wanted to resolve is whether the loss of  
SMCs within the media is due to in situ destruction or their 
transmigration from the media to the neointima. This study 
showed that the loss of  cells from the media of  allograft 
vessels is the result of  cytolytic cell-induced apoptosis, but 
not depopulation resulting from SMC transmigration.[11] In 
addition, studies on nonimmunosupressed and cyclosporin 
(CsA) suppressed rat aortic allografts showed that the 
cells present in allograft neointima originate from the 
recipient.[11,20,21] These results created new questions: What 
is the source and identity of  recipient cells that accumulate 
in the graft neointima and what is their route of  entry into 
the allograft intima? Although some of  the studies in rodent 
and human allografts show that neointimal SMCs originating 
from the circulating mesenchymal progenitor cells probably 
derived from the recipient bone marrow [Figure 4],[22-24] other 
studies indicate that the bone marrow is not a major source 
of cells populating graft neointima[19,20,23] and that circulation-
derived CD34+ hematopoietic progenitor cells give rise to 
smooth muscle progenitor cells that may eventually migrate 
to the graft vessels.[18,25] Interestingly, several recent studies 
on the origin of  the SMCs conclude that the bone marrow-
derived cells do not participate in neointima formation,[5,26,27] 
and point to the arterial adventitia as the major source of  
neointimal SMCs.[16,28] In view of this persisting controversy 
[Figure 4], it still remains to be defined how various cell 
types, both donor and host origin, contribute to the formation 
of  neointima during chronic allograft rejection. This is a 
significant issue that warrants further investigation.
Migration and proliferation of SMCs
Although very little is known about the route and 
mechanisms, operating in the migration of  SMCs into 
the intima during chronic rejection per se, a plethora of  
information on the SMC movement in various model 
systems may apply to the SMC movement during 
vessel wall remodeling in chronic rejection. It is well-
established that the cell migration starts when cell 
surface receptors are stimulated, which, in turn, initiates 
a cascade of  cytoskeleton remodeling events such as 
actin polymerization, repositioning of  the microtubule 
organizing center (MTOC), changing the adhesiveness 
to the substratum, and eventually the emergence of  the 
actin-rich leading and trailing edge (uropod) of  the motile 
cell [Figure 5].[18,29,30] Numerous studies indicate that, in 
majority of  cell types, cell adhesion and motility (through 
the actin cytoskeleton remodeling) are under the control 
of  pleiotropic small GTPase RhoA/ROCK and Rac1 
Figure 5: Actin- and RhoA/Rac1 pathway-dependent functions in cell 
migration and transmigration. (a) Migratory and (b) transmigratory 
phenotypes of cells such as smooth muscle cells (SMCs), fi broblasts, 
or macrophages; depend on the polarization of microtubules emanating 
from centriole-containing MTOC (or centrosome) and the formation of 
actin-rich (shown in red) leading (lamellipodium) and trailing (uropod) 
edge. Lamellipodium is able to form, spiky, and actin-rich projections 
called fi lopodia that play a role in sensing of the environment and 
adhesion (together with actin rich focal adhesions and/or stress 
fi bers) to the substratum. Mother and daughter centriole of MTOC 
and microtubules are shown in green. MTOC-derived microtubules 
deliver, via function of molecular motors, various molecules (such as 
actin-binding proteins) and vesicles to proper destinations within the 
cell. (c) Actin dynamics (such as polymerization, depolymerization, 
and binding to its partners) in uropod, lamellipodium, fi lopodia, and 
focal adhesion/stress fi bers are regulated by interplay between small 
GTPase RhoA and Rac1 pathways.[59]
Figure 6: RhoA/Rac1 pathways regulate actin dynamics. RhoA and its 
downstream effector ROCK, and their reciprocal interaction with Rac1, 
regulate (through actin-binding partners: Cofi lin, myosin II, profi lin, 
and vinculin) the pleiotropic actin-dependent processes pivotal for 
cell movement, phagocytosis, and cell differentiation. RhoA pathway 
inhibitors such as Y-27632, exoenzyme C3, and fasudil inhibit SMCs 
migration and may prevent chronic rejection-related vasculopathy.
ba
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pathways [Figures 5 and 6].[31] Accordingly, it has been 
also shown that RhoA activates ROCK1 and ROCK2 in 
SMCs[32] and that the ROCK1 inhibitor Y-27632, RhoA/
RhoB/RhoC inhibitor C3 exoenzyme, and ROCK inhibitor 
fasudil block SMCs migration.[33-35] In addition, studies 
on ROCK1+/–mice indicate that ROCK1 is required for 
the development of  cardiac fibrosis and is also involved in 
myocyte differentiation. The p190-B Rho GAP-deficient 
mice with chronically activated RhoA/ROCK pathway 
have predilection toward myocyte differentiation and the 
treatment of  these mice with the Y-27632 inhibitor down 
regulates myocyte pathway.[32,36] Studies from our laboratory 
showed that Y-27632 inhibitor abrogates chronic rejection 
of  cardiac allografts in a rat model and inhibits intimal 
thickening of  the allograft vessels.[37] These findings suggest 
that this inhibitor prevents or disrupts migration of  SMCs 
into the intima. Interestingly, statins, which are used for 
treatment of  hyperlipidemias by affecting synthesis of  
small GTPase proteins, also inhibit SMC proliferation and 
migration.[38,39]
It is well-established that after migration to the intima 
SMCs undergo extensive proliferation. Although the 
signaling pathways responsible for SMCs proliferation 
during alloimmune response are not fully understood, it 
seems that platelet-derived growth factor (PDGF) is one 
of  the regulators involved.[40,41] Recent studies of  chronic 
allograft vasculopathy demonstrated that the enzyme 
transglutaminase 2 (TG2)-mediated activation of  β-catenin 
signaling plays a major role in proliferation of  neointimal 
SMCs in murine cardiac allograft system.[42]
Over the years, several therapeutically important drugs have 
been identified that prevent vessel wall thickening by either 
inhibiting SMC migration or inhibiting cell cycle-progression, 
and thus decreasing SMC proliferation or both. For example, 
sabiporide, a new Na/H exchanger inhibitor,[43] rapamycin,[44] 
taxol,[45] and antidiabetic and anti-inflammatory drug 
troglitazone,[46] all inhibit cell cycle progression and SMC 
migration. However, although these drugs are often beneficial 
in preventing vessel remodeling during atherosclerotic 
disease in humans and some, like Y-27632 inhibitor, block 
chronic rejection in rodents.[37,47,48] So far none have been 
proven effective in inhibition of chronic rejection in humans. 
This underscores the fact that chronic rejection is far more 
complex than simple SMC migration and proliferation in 
the vessel intima and that chronic rejection prevention or 
treatment will probably require complex and multitargeted 
approaches, including the manipulation of immune cells and 
immunological response. One of  the most recent promising 
cell types, whose modulation may improve allograft 
functions, is the macrophages.
Macrophages and graft injury
Macrophages are one of  the most plastic and mysterious 
cell types of  immune response and allograft injury. 
Macrophages are professional phagocytes and antigen-
presenting cells [Figure 7], which differentiate from 
circulating peripheral blood monocytes. In response to 
different cytokine signals they differentiate into classically 
activated M1-inflammatory macrophages (CAM) or 
alternatively activated anti-inflammatory M2 macrophages 
(AAM).[49,50] M1 macrophages are highly effective in 
phagocytosis, they produce high level of  inducible nitric 
oxide synthase 2 (iNOS) and potent proinflammatory 
cytokines such as interleukin (IL)-1, IL-6, and IL-23; thus, 
may participate in allograft damage. M2 macrophages 
produce anti-inflammatory cytokines (IL-10), and growth 
factors (PDGF, transforming growth factor (TGF)-β, 
endothelial growth factor (EGF), vascular endothelial 
growth factor (VEGF), and chitinase and chitinase-like 
proteins involved in immunosuppression, extracellular 
matrix turnover, and tissue repair). M2 macrophages 
are also involved in angiogenesis and tissue remodeling, 
and therefore, they may promote allograft damage repair. 
Numerous studies showed that macrophages infiltrate 
allografts and allograft vessel intima during both acute 
and chronic rejection. In rodent models, depletion 
of  macrophages inhibits transplant vasculopathy and 
improves allograft functions.[49,51,52] Recently, a new 
type of  macrophage called regulatory macrophage or 
Mreg has been identified, which seem to play an anti-
inflammatory function. Recent pilot study of  adoptive 
transfer of  donor-derived Mregs into human recipients 
of  kidney allografts demonstrated a dramatic lowering of  
the immunosuppression drugs in transplant patients and 
improved allograft outcome.[53,54] Whether this improved 
graft function is the result of  reduced chronic rejection 
remains unknown.
Macrophages present within the transplanted organs derive 
from two main sources: 1. Donor-derived macrophages, 
which are present in the organ during transplantation, and 
2. recipient-derived macrophages; which enter the graft after 
transplantation. Within first few weeks posttransplantation 
donor-derived macrophages proliferate, and subsequently, 
in non-rejecting graft, their number gradually declines. 
Studies on kidney transplant models showed that during 
acute rejection there are massive accumulation of  
recipient-derived macrophages and their proliferation 
within the allograft and thus amplify rejection response.[52] 
Although it remains unknown how exactly macrophages 
promote development of  chronic rejection it seems that 
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may promote cell death (through the production of  nitric 
oxide), fibrosis (through the release of  metalloproteases 
and (TGF)-β, smooth muscle proliferation (via release 
of  platelet derived growth factor PDGF), and cytokine-
mediated inflammation (via IL-1 and tumor necrosis factor 
alfa (TNF)-α.[52] Recent studies of  the role of  macrophages 
in chronic rejection in rat cardiac allograft model using 
noninvasive magnetic resonance imaging (MRI) tracking 
of  macrophages labeled with micron-sized paramagnetic 
iron oxide particles showed that the number of  recipient-
derived macrophages increases during development of  
chronic rejection, and that persistence of  macrophage 
accumulation after postacute rejection stage may be an 
indicator of  developing chronic rejection (CR).[55]
Macrophage functions such as cell polarity, motility, 
interactions with extracellular matrix, phagocytosis, and 
antigen presentation; are all actin cytoskeleton-dependent, 
and as such they are regulated by small GTPase RhoA/
ROCK and Rac1 pathways [Figures 3, 6 and 7].[56-58] This, 
in turn, suggests that inhibitors of  these pathways could 
be potentially used to modulate macrophage functions 
in chronic rejection. Indeed, recent (unpublished) 
studies from our laboratory indicate that RhoA pathway 
inhibitor Y-27632, which abrogates chronic rejection of  
heart allografts in rodent models, dramatically modifies 
macrophage morphology and polarization [Figure 8]. 
Thus, it seems that together with the SMCs, different 
aspects of  macrophage-related alloimmune response 
may be promising targets for novel antichronic rejection 
therapies.
Summary
Chronic allograft rejection is a major hurdle to transplant 
success in the clinic and overcoming this hurdle is critical 
to advance transplant medicine. One of  the most striking 
features of  chronic rejection is the concentric neointima 
formation affecting virtually all blood vessels in the 
transplanted organs. The mechanisms behind this distinct 
pathology remain incompletely defined and multiple 
mechanisms, pathways, and cell types have been implicated 
in this process. Further understanding of  the fundamental 
mechanisms related to cell motility, migration, and 
polarization as well as tissue repair and remodeling may 
lead to the development of  new therapies to treat or prevent 
chronic allograft rejection.
Figure 8: RhoA pathway inhibitor Y-27632 abrogates macrophage 
polarization and podosome formation. The unpublished data from 
our laboratory show that Y-27632 inhibitor prevents actin-dependent 
polarization of macrophage morphology and formation of actin-
containing podosome rosette. (a) Mouse control macrophage shows 
highly elongated and polarized phenotype and the podosomes 
clustered into the rosette. (b) Macrophage incubated in the presence of 
Y-27632 inhibitor does not polarize and shows low number of dispersed 
podosomes. Actin was stained red with rhodamine-conjugated 
phalloidin. Yellow tint of podosome rosette in the control macrophage 




Figure 7: Macrophage actin-pendent functions. (a) Macrophage 
phagocytosis and down-the-road antigen presentation depend on 
the actin cytoskeleton. Engulfment (phagocytosis) of foreign material, 
such as bacteria, viruses, dead cells, or cell debris is facilitated by the 
actin-myosin contractile-dependent phagosome formation at the cell 
surface. Once inside the cytoplasm, phagosome (containing ingested 
material) is then fused with the endosomes and lysosomes, leading to 
ingested material degradation and/or further processing into peptides 
through the proteasomal pathway. The resulting antigenic peptides 
are presented on the cell surface by major histocompatibility complex 
(MHC) class I and/or MHC class II molecules. (b) Macrophage migration 
not only depends on the formation and function of actin rich leading and 
trailing edge, but also on their ability to digest and degrade extracellular 
matrix. Extracelluar matrix degradation depends on the function of 
actin- and metalloproteinase-rich organelles called the podosomes. 
Podosomes play a role in cellular motility within tissue by coordination 
of degradation of the extracellular matrix with cellular movement. In 
macrophages the podosomes are either dispersed on the cell surface 
or they are clustered into higher order complex called the podosomal 
rosette. Podosomal metalloproteinases (shown in light green), which 
are used for matrix degradation, are delivered to the podosomes via 
microtubules emanating from microtubule organizing center (MTOC) 
(shown in dark green) and molecular motors.[60]
a
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